Literature DB >> 21327506

Heparin-induced thrombocytopenia: present and future.

Adam Cuker1.   

Abstract

Heparin-induced thrombocytopenia (HIT) is a prothrombotic and potentially devastating complication of heparin therapy due to formation of platelet-activating antibodies against complexes of platelet factor 4 and heparin. Over the last several decades, great advances in our understanding of HIT have elevated a once enigmatic syndrome, the mere existence of which was doubted by the medical community, to a well-characterized disorder. Nevertheless, critical questions remain unanswered. The objective of this review is to examine our current understanding of the epidemiology, pathophysiology, diagnosis, and management of HIT and to highlight areas of future inquiry.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21327506     DOI: 10.1007/s11239-011-0569-6

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  133 in total

1.  A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study.

Authors:  Steven W Boyce; Dennis F Bandyk; John R Bartholomew; James N Frame; Lawrence Rice
Journal:  Am J Ther       Date:  2011-01       Impact factor: 2.688

Review 2.  Clinical practice. Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  N Engl J Med       Date:  2006-08-24       Impact factor: 91.245

3.  Risk of anaphylaxis after reexposure to intravenous lepirudin in patients with current or past heparin-induced thrombocytopenia.

Authors:  Gustavo A Cardenas; Steven R Deitcher
Journal:  Mayo Clin Proc       Date:  2005-04       Impact factor: 7.616

Review 4.  Safety of low-molecular-weight heparin in pregnancy: a systematic review.

Authors:  B J Sanson; A W Lensing; M H Prins; J S Ginsberg; Z S Barkagan; E Lavenne-Pardonge; B Brenner; M Dulitzky; J D Nielsen; Z Boda; S Turi; M R Mac Gillavry; K Hamulyák; I M Theunissen; B J Hunt; H R Büller
Journal:  Thromb Haemost       Date:  1999-05       Impact factor: 5.249

5.  Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia.

Authors:  C Pouplard; S Iochmann; B Renard; O Herault; P Colombat; J Amiral; Y Gruel
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

6.  Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4.

Authors:  J G Kelton; J W Smith; T E Warkentin; C P Hayward; G A Denomme; P Horsewood
Journal:  Blood       Date:  1994-06-01       Impact factor: 22.113

7.  Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.

Authors:  Bruce E Lewis; Diane E Wallis; Fred Leya; Marcie J Hursting; John G Kelton
Journal:  Arch Intern Med       Date:  2003 Aug 11-25

8.  Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: a survey of North American specialized coagulation laboratories.

Authors:  Elizabeth A Price; Catherine P M Hayward; Karen A Moffat; Jane C Moore; Theodore E Warkentin; James L Zehnder
Journal:  Thromb Haemost       Date:  2007-12       Impact factor: 5.249

9.  Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia.

Authors:  L Ziporen; Z Q Li; K S Park; P Sabnekar; W Y Liu; G Arepally; Y Shoenfeld; T Kieber-Emmons; D B Cines; M Poncz
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

10.  Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive.

Authors:  S Selleng; B Malowsky; U Strobel; A Wessel; T Ittermann; H-G Wollert; T E Warkentin; A Greinacher
Journal:  J Thromb Haemost       Date:  2009-09-28       Impact factor: 5.824

View more
  11 in total

1.  The Clinical Utility of the Heparin Neutralization Assay in the Diagnosis of Heparin-Induced Thrombocytopenia.

Authors:  Gang Zheng; Michael B Streiff; Clifford M Takemoto; Jennifer Bynum; Elise Gelwan; Jayesh Jani; Danielle Judge; Thomas S Kickler
Journal:  Clin Appl Thromb Hemost       Date:  2017-08-04       Impact factor: 2.389

2.  Development of an algorithm for the systematic evaluation of patients with suspected heparin-induced thrombocytopenia.

Authors:  Julie Thomson; Philip Kuriakose; Long To; Michael Peters; James Kalus
Journal:  J Thromb Thrombolysis       Date:  2019-04       Impact factor: 2.300

3.  Nattokinase-heparin exhibits beneficial efficacy and safety-an optimal strategy for CKD patients on hemodialysis.

Authors:  Hao Wu; Huan Wang; Wei Li; Chi Zhang; Yushan Liu; Feng Xu; Jiepeng Chen; Lili Duan; Fengjiao Zhang
Journal:  Glycoconj J       Date:  2019-02-20       Impact factor: 2.916

4.  Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin-Like Receptors (KIR) Types on Heparin-Induced Thrombocytopenia (HIT).

Authors:  Jason H Karnes; Christian M Shaffer; Robert Cronin; Lisa Bastarache; Silvana Gaudieri; Ian James; Rebecca Pavlos; Heidi E Steiner; Jonathan D Mosley; Simon Mallal; Joshua C Denny; Elizabeth J Phillips; Dan M Roden
Journal:  Pharmacotherapy       Date:  2017-09-04       Impact factor: 4.705

5.  Rational design and characterization of D-Phe-Pro-D-Arg-derived direct thrombin inhibitors.

Authors:  Ana C Figueiredo; Cristina C Clement; Sheuli Zakia; Julian Gingold; Manfred Philipp; Pedro J B Pereira
Journal:  PLoS One       Date:  2012-03-23       Impact factor: 3.240

6.  Elevated heparin-induced antibodies are more common in diabetic patients with vascular disease.

Authors:  Joseph J Naoum; Nibal R Chamoun; Mitul S Patel; Tiffany K Street; Mazen Haydar; Jean Bismuth; Hosam F El-Sayed; Mark G Davies; Alan B Lumsden; Eric K Peden
Journal:  Thrombosis       Date:  2014-02-06

7.  Clinical validation of immunoassay HemosIL® AcuStar HIT-IgG (PF4-H) in the diagnosis of Heparin-induced thrombocytopenia.

Authors:  Zeina Marashi-Sabouni; Caroline Vayne; Manal Ibrahim-Kosta; Catherine Guidon; Anderson Loundou; Eve Anne Guery; Pierre-Emmanuel Morange; Laurence Camoin-Jau
Journal:  J Thromb Thrombolysis       Date:  2021-01-01       Impact factor: 2.300

8.  A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record.

Authors:  Jason H Karnes; Robert M Cronin; Jerome Rollin; Alexander Teumer; Claire Pouplard; Christian M Shaffer; Carmelo Blanquicett; Erica A Bowton; James D Cowan; Jonathan D Mosley; Sara L Van Driest; Peter E Weeke; Quinn S Wells; Tamam Bakchoul; Joshua C Denny; Andreas Greinacher; Yves Gruel; Dan M Roden
Journal:  Thromb Haemost       Date:  2014-12-11       Impact factor: 5.249

9.  Heparin-induced thrombocytopenia in a patient with colon cancer.

Authors:  Somsri Wiwanitkit; Viroj Wiwanitkit
Journal:  Indian J Med Paediatr Oncol       Date:  2012-10

10.  Mitral valve and right ventricular thrombi possibly caused by heparin-induced thrombocytopenia.

Authors:  Ahmet Güner; Anıl Avcı; Abdulkadir Uslu; Semih Kalkan; Mehmet Özkan
Journal:  Anatol J Cardiol       Date:  2019-09       Impact factor: 1.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.